ff-10832 gemcitabine liposome
Biliary Tract Cancer
Fujifilm Pharmaceuticals U.S.A., Inc.Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 73/ 100
Competitive context
83 Active assets in the Biliary Tract Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Merck Sharp & Dohme LLC | Phase 3 | BB |
Epirubicin Merck Sharp & Dohme LLC | Phase 3 | BB |
Pembrolizumab Merck Sharp & Dohme LLC | Phase 3 | BB |
Capecitabine Zhejiang Cancer Hospital | Phase 2 | BB |
FLUOROURACILUM Shenzhen Xinhe Biomedical | Phase 2 | BB |
View all 50 →
Same molecule, other indications
ff-10832 gemcitabine liposome is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →